Oticon Real vs Otofonix Groove

The Oticon Real is a premium prescription behind-the-ear hearing aid released in 2023, priced at $4,798. In HearAdvisor's lab testing, it earned an A grade with a SoundScore of 4.7/5, placing it in the top 10% of the 39 prescription hearing aids tested and ranking #5 in its category. Speech performance is a clear strength for the Oticon Real. Speech in quiet scored a strong 4.0/5, sitting 0.64 points above the category average. Speech in noise measured 2.9/5—above the category average by 0.82 points, though still mixed in absolute terms. This combination makes it a solid choice for listeners prioritizing conversation clarity across different environments. Feedback handling scored a strong 4.0/5 in absolute terms, though this falls 0.72 points below the category average of 4.72/5. Own voice comfort scored 2.4/5, which is 0.30 points below the category average—a potential consideration for those sensitive to how their own voice sounds. Music streaming performance was mixed at 2.8/5, essentially matching the category average. The Oticon Real is a two-time Expert's Choice Award winner (2023, 2024) and offers flexible power options with both rechargeable and disposable batteries. It supports iPhone and Android streaming along with hands-free calling. Within its premium price tier, it faces strong competition from devices like the Phonak Sphere Infinio and Oticon Intent, but remains a compelling option for users who prioritize speech intelligibility and are willing to invest in top-tier technology.

The Otofonix Groove is a behind-the-ear prescription hearing aid priced at $795, earning a C grade with a SoundScore of 2.7/5 in our lab testing. This rechargeable BTE ranks #38 of 39 devices in the prescription hearing aid category, placing it in the bottom 5% of its class. In our testing, the Groove demonstrated excellent feedback handling at 5.0/5, scoring 0.28 points above the category average. This represents a genuine strength, with the device maintaining stability during our standardized challenge motions. However, speech performance was significantly limited, with speech in quiet scoring 1.0/5 (2.40 points below the category average of 3.40) and speech in noise also at 1.0/5 (1.11 points below average). Music streaming was not functional in our tests, scoring 0.0/5 against a category average of 2.76. Own-voice comfort also fell well below typical prescription hearing aid performance at 0.4/5, which is 2.30 points below the category average. At this price point, several lower-cost alternatives delivered stronger overall performance in our testing. Consumers seeking value in the prescription category may want to explore other options, though those requiring robust feedback control in a rechargeable BTE format may find the Groove's stability noteworthy despite its other limitations.